Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction

Lea E. Widdice, David I. Bernstein, Eduardo L. Franco, Lili Ding, Darron R. Brown, Aaron C. Ermel, Lisa Higgins, Jessica A. Kahn

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. Methods: Men aged 14–26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013–2014 (N = 400) and 2016–2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. Results: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44–0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34–0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.

Original languageEnglish (US)
Pages (from-to)6832-6841
Number of pages10
JournalVaccine
Volume37
Issue number45
DOIs
StatePublished - Oct 23 2019

Fingerprint

Papillomavirus Vaccines
Papillomaviridae
Vaccines
vaccines
Propensity Score
dosage
Human papillomavirus 1
odds ratio
confidence interval
Human papillomavirus 6
Logistic Models
Odds Ratio
herds
Confidence Intervals
Human papillomavirus 11
sexually transmitted diseases
Papillomavirus Infections
Chi-Square Distribution
Sexually Transmitted Diseases
infection

Keywords

  • Effectiveness
  • Herd protection
  • Human papillomavirus
  • Male
  • Prevalence
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. / Widdice, Lea E.; Bernstein, David I.; Franco, Eduardo L.; Ding, Lili; Brown, Darron R.; Ermel, Aaron C.; Higgins, Lisa; Kahn, Jessica A.

In: Vaccine, Vol. 37, No. 45, 23.10.2019, p. 6832-6841.

Research output: Contribution to journalArticle

Widdice, Lea E. ; Bernstein, David I. ; Franco, Eduardo L. ; Ding, Lili ; Brown, Darron R. ; Ermel, Aaron C. ; Higgins, Lisa ; Kahn, Jessica A. / Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. In: Vaccine. 2019 ; Vol. 37, No. 45. pp. 6832-6841.
@article{b23e91ab39a04353bf6bbff3d1441e74,
title = "Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction",
abstract = "Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. Methods: Men aged 14–26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013–2014 (N = 400) and 2016–2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. Results: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23{\%} to 44{\%} (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29{\%} to 20{\%}; 31{\%} decrease; odds ratio [OR] = 0.62, 95{\%} confidence interval [CI] = 0.44–0.88) and unvaccinated men (32{\%} to 21{\%}; 36{\%} decrease; OR = 0.56, 95{\%}CI = 0.34–0.86); there was a non-significant decrease (21{\%}) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.",
keywords = "Effectiveness, Herd protection, Human papillomavirus, Male, Prevalence, Vaccine",
author = "Widdice, {Lea E.} and Bernstein, {David I.} and Franco, {Eduardo L.} and Lili Ding and Brown, {Darron R.} and Ermel, {Aaron C.} and Lisa Higgins and Kahn, {Jessica A.}",
year = "2019",
month = "10",
day = "23",
doi = "10.1016/j.vaccine.2019.08.052",
language = "English (US)",
volume = "37",
pages = "6832--6841",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "45",

}

TY - JOUR

T1 - Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction

AU - Widdice, Lea E.

AU - Bernstein, David I.

AU - Franco, Eduardo L.

AU - Ding, Lili

AU - Brown, Darron R.

AU - Ermel, Aaron C.

AU - Higgins, Lisa

AU - Kahn, Jessica A.

PY - 2019/10/23

Y1 - 2019/10/23

N2 - Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. Methods: Men aged 14–26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013–2014 (N = 400) and 2016–2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. Results: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44–0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34–0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.

AB - Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. Methods: Men aged 14–26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013–2014 (N = 400) and 2016–2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. Results: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44–0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34–0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.

KW - Effectiveness

KW - Herd protection

KW - Human papillomavirus

KW - Male

KW - Prevalence

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85072708010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072708010&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.08.052

DO - 10.1016/j.vaccine.2019.08.052

M3 - Article

C2 - 31582269

AN - SCOPUS:85072708010

VL - 37

SP - 6832

EP - 6841

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 45

ER -